Now available TECVAYLI™

TECVAYLI™ (teclistamab-cqyv) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Please see full prescribing information here.